Federal prosecutors and securities regulators have gone after large companies for violations of the Foreign Corrupt Practices Act, which prohibits them from bribing foreign officials.
But high medical costs contributed to results that disappointed Wall Street, and the companyβs stock fell on the news that it had made less than analysts expected.